Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ioflupane 123I

Next Previous
Drug Profile

Ioflupane 123I

Alternative Names: DaTSCAN; DaTscan; Ioflupane (123I); Radio-labelled ioflupane; β-CIT-FP

Latest Information Update: 04 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GE Healthcare
  • Class Diagnostic agents; Nortropanes; Small molecules
  • Mechanism of Action Dopamine plasma membrane transport protein modulators; Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dementia; Lewy body disease; Multiple system atrophy; Parkinsonian disorders; Progressive supranuclear palsy

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 27 Apr 2015 Ioflupane 123I licensed to Nihon Medi-Physics in Japan before April 2015
  • 07 May 2014 Efficacy and adverse events data from a pooled analysis of four clinical trials in Parkinsonian disorders presented at the 66th Annual Meeting of the American Academy of Neurology(AAN-2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top